Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
or

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)
886.98 +27.25 (+3.17%) 19:04 ET [NYSE]
878.70 x 5 888.00 x 1
Realtime by (Cboe BZX)
878.70 x 5 888.00 x 1
Realtime 886.98 +2.44 (+0.28%) 19:04 ET
Quote Overview for Fri, Apr 25th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
851.07
Day High
884.54
Open 859.66
Previous Close 859.73 859.73
Volume 3,397,871 3,397,871
Avg Vol 3,992,070 3,992,070
Stochastic %K 94.11% 94.11%
Weighted Alpha +17.32 +17.32
5-Day Change +44.58 (+5.31%) +44.58 (+5.31%)
52-Week Range 677.09 - 972.53 677.09 - 972.53
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 815,170,176
  • Shares Outstanding, K 948,170
  • Annual Sales, $ 45,043 M
  • Annual Income, $ 10,590 M
  • EBIT $ 12,899 M
  • EBITDA $ 14,666 M
  • 60-Month Beta 0.51
  • Price/Sales 17.46
  • Price/Cash Flow 58.27
  • Price/Book 55.17

Options Overview Details

View History
  • Implied Volatility 37.76% ( -1.49%)
  • Historical Volatility 54.93%
  • IV Percentile 76%
  • IV Rank 36.37%
  • IV High 64.53% on 04/07/25
  • IV Low 22.46% on 06/28/24
  • Put/Call Vol Ratio 0.54
  • Today's Volume 48,720
  • Volume Avg (30-Day) 37,496
  • Put/Call OI Ratio 1.04
  • Today's Open Interest 288,672
  • Open Int (30-Day) 268,236

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 25 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 3.52
  • Number of Estimates 9
  • High Estimate 4.64
  • Low Estimate 2.68
  • Prior Year 2.58
  • Growth Rate Est. (year over year) +36.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
677.09 +30.64%
on 04/07/25
Period Open: 852.35
885.58 -0.12%
on 04/25/25
+32.19 (+3.78%)
since 03/25/25
3-Month
677.09 +30.64%
on 04/07/25
Period Open: 785.41
935.63 -5.46%
on 03/03/25
+99.13 (+12.62%)
since 01/24/25
52-Week
677.09 +30.64%
on 04/07/25
Period Open: 724.87
972.53 -9.05%
on 08/22/24
+159.67 (+22.03%)
since 04/25/24

Most Recent Stories

More News
Jobs Reports Due South of the Border Next Week

U.S. Monday Featured Earnings Welltower Inc. (NYSE:WELL) (Q1) EPS of $1.15, compared to $1.01 ...

META : 547.27 (+2.65%)
AAPL : 209.28 (+0.44%)
KO : 71.91 (-0.84%)
CVX : 138.73 (-0.24%)
WELL : 146.96 (-0.53%)
CI : 335.36 (-0.10%)
GIL.TO : 58.89 (+0.07%)
MSFT : 391.85 (+1.17%)
MA : 533.48 (-0.37%)
QCOM : 148.56 (+0.92%)
WELL.TO : 4.01 (+1.26%)
WM : 228.31 (+0.37%)
Why Novo Nordisk Stock Dropped Today

Ignore the noise. Novo Nordisk stock is a bargain.

NVO : 62.08 (-0.88%)
LLY : 884.54 (+2.89%)
The Best Stock to Buy With Less Than $60 in the Market Sell-Off

Plenty of stocks with attractive businesses trade on the market for hundreds of dollars per share -- or more. However, it's possible to find excellent stocks that may become undervalued when either the...

NVO : 62.08 (-0.88%)
LLY : 884.54 (+2.89%)
Roche's Q1 Sales Increase Y/Y on Solid Performance of Key Drugs

Swiss pharma giant Roche Holding AG RHHBY posted strong growth in the first quarter of 2025. Sales increased 7% year over year to CHF 15.4 billion and were up 6% at constant exchange rates (CER).(Find...

NVO : 62.08 (-0.88%)
LLY : 884.54 (+2.89%)
REGN : 602.64 (+0.48%)
RHHBY : 39.5200 (-0.58%)
Forget Zepbound: Eli Lilly Has Its Next Billion-Dollar Weight Loss Drug

Eli Lilly (NYSE: LLY) has been growing its sales at a good clip over the past year. This is partly thanks to Zepbound, a weight loss medicine that's already generating more than $1 billion in quarterly...

LLY : 884.54 (+2.89%)
Eli Lilly Nails Oral GLP-1 Trial—Here’s What It Means for LLY

Take a deep dive into Eli Lilly's latest clinical GLP-1 results that sent shares soaring. The company has a big opportunity to serve needle-phobic patients.

NVO : 62.08 (-0.88%)
LLY : 884.54 (+2.89%)
PFE : 22.92 (+0.61%)
Is Eli Lilly Stock Going to $900? 1 Wall Street Analyst Thinks So.

Rather counterintuitively, following some promising news about a pipeline drug, one analyst tracking Eli Lilly (NYSE: LLY) stock cut his price target on the pharmaceutical giant. Even though that reduction...

NFLX : 1,101.53 (+0.42%)
NVDA : 111.01 (+4.30%)
LLY : 884.54 (+2.89%)
Novo Nordisk Investors Just Got Terrible News. Should You Sell the Stock?

Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has been struggling during the past year. Its financial results -- though strong by comparison to most of its peers -- haven't been as good as...

NVO : 62.08 (-0.88%)
LLY : 884.54 (+2.89%)
Is Eli Lilly Stock a Buy?

The competitive landscape for GLP-1 agonist weight loss drugs has undergone a significant shake-up.

NVO : 62.08 (-0.88%)
LLY : 884.54 (+2.89%)
PFE : 22.92 (+0.61%)
Why Vertex Pharmaceuticals Was Such a Healthy Stock on Tuesday

Vertex Pharmaceuticals (NASDAQ: VRTX) had a fine Tuesday on the stock exchange. The biotech 's shares closed the day nearly 3% higher in price, on the back of two positive mentions by analysts tracking...

NFLX : 1,101.53 (+0.42%)
NVDA : 111.01 (+4.30%)
UBS : 30.02 (+0.70%)
VRTX : 493.84 (+0.28%)
LLY : 884.54 (+2.89%)
PFE : 22.92 (+0.61%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Average short term outlook on maintaining the current direction.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure...

See More

Key Turning Points

3rd Resistance Point 930.90
2nd Resistance Point 908.24
1st Resistance Point 896.39
Last Price 884.54
1st Support Level 861.88
2nd Support Level 839.22
3rd Support Level 827.37

See More

52-Week High 972.53
Last Price 884.54
Fibonacci 61.8% 859.67
Fibonacci 50% 824.81
Fibonacci 38.2% 789.95
52-Week Low 677.09

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective